Abstract
Introduction
The drug therapy of acute myeloid leukemia (AML) and adult acute lymphoblastic
leukemia (ALL) is largely based on chemotherapy regimens that have changed
little in the past few decades. Patient outcomes for both diseases remain
poor, particularly for elderly and high-risk patients. As the limits of
cytotoxic chemotherapy are being reached, an unmet need remains for novel,
improved therapies.
Scope of this research
- Analysis of the AML and adult ALL market based on a survey of 180 acute
leukemia specialists, supported by interviews with key opinion leaders.
- Segmentation of the AML and adult ALL populations by age group and risk
group, respectively
- In-depth analysis of treatment patterns, regimens prescribed and treatment
outcomes for AML and adult ALL by age group and risk group, respectively
- Discussion of unmet needs and overview of late-stage pipeline drugs and
marketed drugs investigated for expansion into the AML and adult ALL settings
Research and analysis highlights
The only molecular targeted therapy approved for use in AML is Mylotarg
(gemtuzumab ozogamicin; Wyeth) but it' s use is limited to elderly, relapsed
patients who are not candidates for other chemotherapy. A number of molecular
targeted therapies are currently in development for AML but are expected to
have minimal impact on patient outcomes.
Gleevec (imatinib; Novartis) is the only molecular targeted therapy used
extensively in the treatment of adult ALL. To date, the second generation
tyrosine kinase inhibitors Sprycel (dasatinib; Bristol-Myers Squibb) and
Tasigna (nilotinib; Novartis) have limited use in the treatment of the disease.
Hematopoietic stem cell transplantation (HSCT) has a central role in the
management of both AML and adult ALL. However, it remains an underutilized
procedure and its use is often delayed beyond its optimal timing. Research
efforts are required to optimize the use of this potentially curative approach.
Key reasons to purchase this research
- Understand prescribing trends in the AML and adult ALL markets
- Examine unmet need within the AML and adult ALL markets and identify
opportunities for new product development
- Enhance commercial positioning by increasing understanding of current
dynamics within the AML and adult ALL markets
| 
View Cart
